Literature DB >> 18778364

A RNA transcript (Heg) in mononuclear cells is negatively correlated with CD14 mRNA and TSH receptor autoantibodies.

N J Christensen1, G Habekost, P Bratholm.   

Abstract

During a study of gene expression of foxp3 in blood mononuclear cells we observed a DNA product of an unknown RNA fragment. The area of this peak correlated with CD14 mRNA in a small group of subjects. The sequence was localized to chromosome 1. We tested the hypothesis that gene expression of the poly A(-) transcript (designated Heg) in mononuclear cells was correlated with CD14 mRNA in normal subjects and with CD14 mRNA and TSH receptor autoantibodies in patients with acute and untreated Graves' disease. mRNA was expressed in amol/microg DNA. The main study groups were: (i) normal subjects; (ii) patients with early and untreated Graves' disease; and (iii) patients with Graves' disease studied after treatment. In 18 normal subjects and in 20 patients with treated Graves' disease CD14 mRNA was negatively correlated with Heg (P < 0.001). In 17 untreated patients with Graves' disease Heg and thyroid receptor autoantibodies were negatively correlated (P < 0.009). Incubation studies with mononuclear cells showed that the addition of a fragment of the central part of Heg (949 bases) to mononuclear cells decreased CD14 mRNA markedly to zero or nearly zero (P < 0.001). This response was not specific in the sense that siRNA and lipopolysaccharide also decreased CD14 mRNA, probably due to activation of the CD14/Toll-like receptor complex. Single-stranded RNA is likely to increase interferon production. Due to the anti-inflammatory effect Heg may also inhibit the early phase of TSH receptor autoantibody production.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18778364      PMCID: PMC2612712          DOI: 10.1111/j.1365-2249.2008.03744.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  9 in total

1.  An expanding universe of noncoding RNAs.

Authors:  Gisela Storz
Journal:  Science       Date:  2002-05-17       Impact factor: 47.728

Review 2.  Specialization and evolution of endogenous small RNA pathways.

Authors:  Elisabeth J Chapman; James C Carrington
Journal:  Nat Rev Genet       Date:  2007-11       Impact factor: 53.242

3.  Subcapsular encounter and complement-dependent transport of immune complexes by lymph node B cells.

Authors:  Tri Giang Phan; Irina Grigorova; Takaharu Okada; Jason G Cyster
Journal:  Nat Immunol       Date:  2007-07-29       Impact factor: 25.606

Review 4.  Multifunctional deadenylase complexes diversify mRNA control.

Authors:  Aaron C Goldstrohm; Marvin Wickens
Journal:  Nat Rev Mol Cell Biol       Date:  2008-03-12       Impact factor: 94.444

5.  UNC93B1 delivers nucleotide-sensing toll-like receptors to endolysosomes.

Authors:  You-Me Kim; Melanie M Brinkmann; Marie-Eve Paquet; Hidde L Ploegh
Journal:  Nature       Date:  2008-02-27       Impact factor: 49.962

6.  Beta2-adrenoceptor desensitization in non-pregnant estrogen-primed rat myometrium involves modulation of oxytocin receptor gene expression.

Authors:  T Engstrøm; P Bratholm; H Vilhardt; N J Christensen
Journal:  J Mol Endocrinol       Date:  1998-04       Impact factor: 5.098

7.  Phosphatase SHP-1 promotes TLR- and RIG-I-activated production of type I interferon by inhibiting the kinase IRAK1.

Authors:  Huazhang An; Jin Hou; Jun Zhou; Wei Zhao; Hongmei Xu; Yuejuan Zheng; Yizhi Yu; Shuxun Liu; Xuetao Cao
Journal:  Nat Immunol       Date:  2008-04-06       Impact factor: 25.606

8.  H11 has dose-dependent and dual hypertrophic and proapoptotic functions in cardiac myocytes.

Authors:  Makoto Hase; Christophe Depre; Stephen F Vatner; Junichi Sadoshima
Journal:  Biochem J       Date:  2005-06-01       Impact factor: 3.857

9.  Sequence- and target-independent angiogenesis suppression by siRNA via TLR3.

Authors:  Mark E Kleinman; Kiyoshi Yamada; Atsunobu Takeda; Vasu Chandrasekaran; Miho Nozaki; Judit Z Baffi; Romulo J C Albuquerque; Satoshi Yamasaki; Masahiro Itaya; Yuzhen Pan; Binoy Appukuttan; Daniel Gibbs; Zhenglin Yang; Katalin Karikó; Balamurali K Ambati; Traci A Wilgus; Luisa A DiPietro; Eiji Sakurai; Kang Zhang; Justine R Smith; Ethan W Taylor; Jayakrishna Ambati
Journal:  Nature       Date:  2008-03-26       Impact factor: 49.962

  9 in total
  6 in total

1.  Decrease in TSH Receptor Autoantibodies during Antithyroid Treatment: Relationship with a Long Noncoding Heg RNA and Cdk1 mRNA in Mononuclear Cells.

Authors:  Niels Juel Christensen; Gurli Habekost; Palle Bratholm
Journal:  ISRN Endocrinol       Date:  2011-07-06

Review 2.  Noncoding RNAs Carried by Extracellular Vesicles in Endocrine Diseases.

Authors:  Margherita A C Pomatto; Chiara Gai; Maria Chiara Deregibus; Ciro Tetta; Giovanni Camussi
Journal:  Int J Endocrinol       Date:  2018-04-01       Impact factor: 3.257

3.  An Intronic HCP5 Variant Is Associated With Age of Onset and Susceptibility to Graves Disease in UK and Polish Cohorts.

Authors:  Laura Claire Lane; Aleksander Kuś; Tomasz Bednarczuk; Artur Bossowski; Jacek Daroszewski; Beata Jurecka-Lubieniecka; Heather Jane Cordell; Simon Henry Schofield Pearce; Timothy Cheetham; Anna Louise Mitchell
Journal:  J Clin Endocrinol Metab       Date:  2020-09-01       Impact factor: 5.958

Review 4.  The Emerging Role of Epigenetics in Autoimmune Thyroid Diseases.

Authors:  Bin Wang; Xiaoqing Shao; Ronghua Song; Donghua Xu; Jin-An Zhang
Journal:  Front Immunol       Date:  2017-04-07       Impact factor: 7.561

Review 5.  Genetics, Epigenetics, Cellular Immunology, and Gut Microbiota: Emerging Links With Graves' Disease.

Authors:  Fangyu Zhou; Xin Wang; Lingjun Wang; Xin Sun; Guiqin Tan; Wenwen Wei; Guangbing Zheng; Xiaomin Ma; Dan Tian; Hongsong Yu
Journal:  Front Cell Dev Biol       Date:  2022-01-04

Review 6.  Emerging Insights Into the Role of Epigenetics and Gut Microbiome in the Pathogenesis of Graves' Ophthalmopathy.

Authors:  Yan Wang; Xiao-Min Ma; Xin Wang; Xin Sun; Ling-Jun Wang; Xin-Qi Li; Xiao-Yan Liu; Hong-Song Yu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-01-05       Impact factor: 5.555

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.